Clinical Trials
6 trialsNCT04662255 2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT01974440 2025-05-25
SELENE
Janssen Research & Development, LLC
Phase 3 Completed
NCT01855750 2025-02-04
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT05431179 2023-04-21
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Oncternal Therapeutics, Inc
Phase 3 Withdrawn
NCT02165397 2021-03-03
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Pharmacyclics LLC.
Phase 3 Completed
NCT01578707 2019-12-18
RESONATEâ„¢
Pharmacyclics LLC.
Phase 3 Completed